Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals Stock
The price for the Acadia Pharmaceuticals stock decreased slightly today. Compared to yesterday there is a change of -€0.240 (-0.950%).
With 27 Buy predictions and not a single Sell prediction Acadia Pharmaceuticals is an absolute favorite of our community.
As a result the target price of 29 € shows a slightly positive potential of 15.81% compared to the current price of 25.04 € for Acadia Pharmaceuticals.
For the coming years our community has positive and negative things to say abot the Acadia Pharmaceuticals stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of Acadia Pharmaceuticals in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acadia Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals | -0.950% | 12.606% | 10.105% | 19.584% | 8.825% | 3.607% | 54.997% |
| Ligand Pharmaceuticals | -3.820% | -0.781% | -9.286% | 117.094% | 53.012% | 313.008% | 171.194% |
| United Therapeutics | -0.730% | 3.809% | -3.937% | 79.784% | 9.057% | 115.741% | 156.044% |
| Ionis Pharmaceuticals Inc. | 0.270% | 8.773% | -33.915% | 39.931% | -28.119% | 35.356% | 47.985% |
Comments
ACADIA Pharmaceuticals (ACAD) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (ACAD) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (ACAD) had its price target raised by BMO Capital Markets from $34.00 to $36.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat